Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 2051 • ACR Convergence 2020
Localized versus Systemic Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Database
Michele Iudici¹, Christian Pagnoux², Delphine Courvoisier³, Pascal Cohen⁴, Mohamed Hamidou⁵, Achille Aouba⁶, François Lifermann⁷, Marc Ruivard⁸, Olivier Aumaitre⁹, Bernard Bonnotte¹⁰, Julien Campagne¹¹, Olivier Decaux¹², Eric Hachulla¹³, Alexandre Karras¹⁴, Chahéra Khouatra¹⁵, Noémie Jourde-Chiche¹⁶, Jean-François Viallard¹⁷, Pascal Godmer¹⁸, Claire Blanchard-Delaunay¹⁹, Alain Le Quellec²⁰, Thomas Quéméneur²¹, Claire de Moreuil²², Alexis Regent⁴, Benjamin Terrier⁴, Luc Mouthon⁴, Loïc Guillevin⁴ and Xavier Puechal⁴, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University and Geneva University Hospitals, Geneva, Switzerland, ²Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Division of rheumatology, Geneva University Hospitals, Geneva, Switzerland, ⁴National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ⁵Department of Internal Medicine, Hôtel-Dieu, CHU Nantes, Nantes, France, ⁶Department of Internal Medicine, CHU Côte de Nacre, Caen, France, ⁷Department of Internal Medicine, CH Côte d’Argent, Dax, France, ⁸Department of Internal Medicine, CHU Estaing, Clermont Ferrand, France, ⁹Department of Internal Medicine, CHU Gabriel Montpied, Clermont Ferrand, France, ¹⁰CHU Dijon, Dijon, France, ¹¹Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, ¹²CHU Rennes, Rennes, France, ¹³Department of Internal Medicine, CHRU, Lille Cedex, France, ¹⁴Department of Nephrology, Hôpital Européen Georges Pompidou, Paris, France, ¹⁵Department of Respiratory Medicine, CHU Louis Pradel, Lyon, France, ¹⁶Department of Nephrology, CHU de la Conception, Marseille, France, ¹⁷Department of Internal Medicine, CHU Haut-Lévêque, Bordeaux, France, ¹⁸Department of Internal Medicine, CH Bretagne Atlantique, Vannes, France, ¹⁹Department of Internal Medicine, CH, Niort, France, ²⁰Department of Internal Medicine, CHU Saint Eloi, Montpellier, France, ²¹Department of Internal Medicine, CH, Valenciennes, France, ²²Department of Internal Medicine, CHU Cavale Blanche, Brest, France
Background/Purpose: The clinical picture at onset and evolution of localized forms of granulomatosis with polyangiitis (L-GPA) have already been investigated but, to our knowledge, have…
Abstract Number: 1426 • ACR Convergence 2020
Prevalence of ANCA-associated Vasculitis and Spatial Association with Quarries in a French Northeast Region: A Capture-recapture and Geospatial Analysis
Stéphane Giorgiutti¹, Yannick Dieudonné¹, Olivier Hinschberger², Benoit Nespola³, Julien Campagne⁴, Hanta Nirina Rakotoarivelo⁵, Thierry Hannedouche⁶, Bruno Moulin⁶, Gilles Blaison⁵, Jean-Christophe Weber⁷, Marie-Caroline Dalmas⁸, Frederic De Blay⁹, Dan Lipsker¹⁰, Francois Chantrel¹¹, Jacques-Eric Gottenberg¹², Yves Dimitrov¹³, Olivier Imhoff¹⁴, Pierre-Edouard Gavand¹⁵, Emmanuel Andres¹⁶, Christian Debry¹⁷, Yves Hansmann¹⁸, Alexandre Klein¹⁹, Caroline Lohmann²⁰, François Mathiaux²¹, Aurélien Guffroy¹, Vincent Poindron¹, Thierry Martin¹, Anne-Sophie Korganow¹ and Laurent Arnaud²², ¹Department of Clinical Immunology and Internal Medicine, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Department of Internal Medicine, Hôpital Emile Muller, Mulhouse, Mulhouse, France, ³Department of Immunobiology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁴Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, ⁵Department of Internal Medicine, Hôpitaux Civils de Colmar, Colmar, France, ⁶Department of Nephrology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁷Department of Internal Medicine, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁸Department of Internal Medicine Endocrinology and Nutrition, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁹Pneumology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹⁰Department of Dermatology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹¹Department of Nephrology, Hôpital Emile Muller, Mulhouse, Strasbourg, France, ¹²Strasbourg University Hospital, Strasbourg, France, ¹³Department of Nephrology, Centre hospitalier de Haguenau, Haguenau, France, ¹⁴Department of Nephrology, Clinique Saint-Anne, Strasbourg, Strasbourg, France, ¹⁵Department of Internal Medicine, Clinique Rhena, Strasbourg, Strasbourg, France, ¹⁶Department of Internal Medicine, Diabete and Metabolic Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹⁷Department of Otorhinolaryngology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹⁸Department of Infectious Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹⁹Department of Nephrology, Hôpitaux Civils de Colmar, Colmar, France, ²⁰Department of Microbiology, Hôpital Emile Muller, Mulhouse, Mulhouse, France, ²¹Department of Biology, Hôpitaux Civils de Colmar, Strasbourg, France, ²²Department of Rheumatology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Background/Purpose: Studies addressing the epidemiology of ANCA-associated vasculitides (AAV) in different countries reported various prevalence rates and suggested that incidence may have increased over the…
Abstract Number: 2052 • ACR Convergence 2020
Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-Associated Vasculitis and Relapsing Disease
Rona Smith¹, David Jayne² and Peter A. Merkel³, ¹University of Cambridge, Cambridge, United Kingdom, ²Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ³Division of Rheumatology University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse…
Abstract Number: 1430 • ACR Convergence 2020
The Role of Lung Biopsy in Pediatric ANCA-associated Vasculitis
Edouard Sayad¹, Tiphanie Vogel¹, David Moreno McNeill¹, Nahir Cortes-Santiago¹, David Spielberg¹, Kalyani Patel¹ and Manuel Silva Carmona¹, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Anca-associated vasculitis (AAV) is characterized by vascular inflammation in multiple organs. The diagnosis can be made clinically using a number of different criteria. The…
Abstract Number: PP02 • ACR Convergence 2020
Low- and Hi-Tech Tools for Enhancing Patient-Hospital Care Team Communication in the Context of Rare Disease
Ida Hakkarinen¹, ¹Vasculitis Patient-Powered Research Network (VPPRN) / Member, Vasculitis Foundation, Greenbelt, MD
Background/Purpose: For over two years, I experienced a variety of disparate symptoms including: joint aches, sinus congestion, shortness of breath and chronic cough. An episode…
Abstract Number: 1431 • ACR Convergence 2020
Interstitial Lung Disease in Patients with ANCA Associated Vasculitis – a Prospective Single Centre Study
Alojzija Hocevar¹, Katja Perdan Pirkmajer¹, Matija Tomsic¹ and Ziga Rotar¹, ¹University Medical Center Ljubljana, LJUBLJANA, Slovenia
Background/Purpose: Recently, an association between anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and interstitial lung disease (ILD) has been uncovered. We aimed to determine the rate…
Abstract Number: 0060 • ACR Convergence 2020
ANCA-associated Vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California
Sandy Lee¹, Patil Injean¹, Paulina Tran², Deepa Panikkath¹ and Christina Downey¹, ¹Loma Linda University Medical Center, Redlands, CA, ²UC Riverside School of Medicine, Riverside, CA
Background/Purpose: ANCA-associated vasculitis (AAV) is often studied in the Caucasian population with few studies looking at the disease in other races. Disease presentation and treatment…
Abstract Number: 1432 • ACR Convergence 2020
Thyroid Disease in Patients with ANCA-Associated Vasculitis
Tanaz Kermani¹, David Cuthbertson², Simon Carette³, Nader Khalidi⁴, Curry L. Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih¹³, Kenneth Warrington¹² and Peter Merkel¹³, ¹University of California Los Angeles, West Hills, CA, ²University of South Florida, Tampa, ³Division of Rheumatology, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah, Salt Lake City, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, ⁸Brigham and Women's, Boston, ⁹University of Pittsburgh, Denver, CO, ¹⁰Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Prior studies have found increased prevalence of thyroid disease in patients with ANCA-associated vasculitis (AAV), especially positive myeloperoxidase (MPO)-ANCA, but a majority of the…
Abstract Number: 0418 • ACR Convergence 2020
Prevalence of Thyroid Disease Among Patients with Vasculitis
Tanaz Kermani¹, David Cuthbertson², Simon Carette³, Nader Khalidi⁴, Curry L. Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih¹³, Kenneth Warrington¹² and Peter Merkel¹³, ¹David Geffen School of Medicine / University of California, Los Angeles, CA, ²University of South Florida, Tampa, ³Division of Rheumatology, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah, Salt Lake City, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, ⁸Brigham and Women's, Boston, ⁹University of Pittsburgh, Denver, CO, ¹⁰Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Previous studies have reported higher risk of thyroid disease in patients with giant cell arteritis (GCA) and ANCA-associated vasculitis (AAV) compared to age- and…
Abstract Number: 1433 • ACR Convergence 2020
Thyroid Disease in ANCA-associated Vasculitis. a Population-based Study
Anna Wilding¹, Rona Smith², David Jayne³, Mårten Segelmark⁴ and Aladdin Mohammad⁵, ¹Lund University, Staffanstorp, Sweden, ²University of Cambridge, Cambridge, United Kingdom, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁴Lund University, Lund, ⁵Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: A higher incidence of thyroid disease has been seen in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We aim to assess the incidence…
Abstract Number: 0432 • ACR Convergence 2020
The Effect on Renal Function of the Complement C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
Peter Merkel¹, Pirow Bekker², Huibin Yue², Catherine Kelleher², Thomas Schall² and David Jayne³, ¹University of Pennsylvania, Philadelphia, PA, ²ChemoCentryx, Mountain View, CA, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom
Background/Purpose: Avacopan, a novel, orally-administered selective antagonist of C5aR, was recently evaluated in a pivotal Phase 3 randomized clinical trial where its use in patients…
Abstract Number: 1434 • ACR Convergence 2020
The Role of Sural Nerve Biopsy in the Diagnosis of Systemic Vasculitis – a Retrospective Study from Two Specialized Centres
Karl Gisslander¹, Lars Dahlin², Rona Smith³, David Jayne³ and Aladdin Mohammad⁴, ¹Lund University, Lund, Sweden, Lund, Sweden, ²Department of Translational Medicine – Hand Surgery, Lund University, Malmö, Sweden, Malmö, Sweden, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁴Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: Vasculitis of the peripheral nervous system is seen mainly in systemic vasculitis involving small and medium sized vessels and in cases of single-organ vasculitis…
Abstract Number: 2641 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics of a Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Jason Springer¹, Tanaz Kermani ², Antoine Sreih ³, Dianne Shaw ⁴, Kalen Young ⁵, Cristina Burroughs ⁶ and Peter Merkel ³, ¹Kansas University Medical Center, Kansas, MO, ²University of California Los Angeles, Los Angeles, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Vasculitis Foundation, North Carolina, ⁵Vasculitis Foundation, Kansas City, MO, ⁶University of South Florida, Tampa, FL
Background/Purpose: To provide a feasible and sustainable platform for conducting patient-centered research in vasculitis, a prospective, international, internet-based registry of patients with vasculitis has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].